ir.acelrx.com ir.acelrx.com

IR.ACELRX.COM

AcelRx Pharmaceuticals, Inc : Investors

Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. 160;at 4:30 pm ET. Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. Monday, August 3, 2015 . 4:30 pm ET  . Click here for webcast. Click here to add this event to your calendar. ACRX Corporate Presentation - 5/7/15. 160; 0.13. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results. Replication or redistribution of E...

http://ir.acelrx.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.ACELRX.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

November

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Sunday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 4.3 out of 5 with 10 reviews
5 star
6
4 star
1
3 star
3
2 star
0
1 star
0

Hey there! Start your review of ir.acelrx.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

CONTACTS AT IR.ACELRX.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
AcelRx Pharmaceuticals, Inc : Investors | ir.acelrx.com Reviews
<META>
DESCRIPTION
Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. 160;at 4:30 pm ET. Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. Monday, August 3, 2015 . 4:30 pm ET  . Click here for webcast. Click here to add this event to your calendar. ACRX Corporate Presentation - 5/7/15. 160; 0.13. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results. Replication or redistribution of E...
<META>
KEYWORDS
1 overview
2 management
3 board of directors
4 pipeline
5 zalviso
6 technology
7 nanotab
8 sufentanil
9 publications
10 business
CONTENT
Page content here
KEYWORDS ON
PAGE
overview,management,board of directors,pipeline,zalviso,technology,nanotab,sufentanil,publications,business,development,news,investors,careers,stock information,corporate governance,news releases,sec filings,analyst coverage,event calendar,e mail alerts
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

AcelRx Pharmaceuticals, Inc : Investors | ir.acelrx.com Reviews

https://ir.acelrx.com

Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. 160;at 4:30 pm ET. Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. Monday, August 3, 2015 . 4:30 pm ET  . Click here for webcast. Click here to add this event to your calendar. ACRX Corporate Presentation - 5/7/15. 160; 0.13. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results. Replication or redistribution of E...

INTERNAL PAGES

ir.acelrx.com ir.acelrx.com
1

Process Calendar

http://ir.acelrx.com/ProcessCalendarRequest.asp?eventId=5200121&OverridePage=irol-EventDetails&checkJS=false

UPGRADE TO PREMIUM TO VIEW 0 MORE

TOTAL PAGES IN THIS WEBSITE

1

LINKS TO THIS WEBSITE

acelrx.com acelrx.com

AcelRx | Development and commercialization of therapies for acute pain

http://www.acelrx.com/about/overview.html

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. In the United States, ARX-04 and Zalviso have completed pivotal Phase 3 placebo-controlled trials resulting in clinically significant acute pain relief (p value 0.001 for both ARX-04 and Zalviso as measured by Summed Pain Intensity Difference to Baseline in Phase 3 studies). Zalviso is currently approved by the European Commission (EC...

acelrx.com acelrx.com

AcelRx | Innovative Therapies for Acute Pain

http://www.acelrx.com/pipeline/arx-04.html

Moderate-to-Severe Acute Pain in Trauma and Ambulatory Care Settings. In situations of trauma or injury, it is advantageous to have a rapid-acting, non-invasive method of treating acute pain. In the battlefield, emergency medicine and ambulatory care environments, patients may not have immediate intravenous (IV) access available. Intramuscular (IM) injections are the current standard of care on the battlefield. ARX-04 Potential Settings of Use. Based on the National Survey of Ambulatory Surgery, in 2006,...

acelrx.com acelrx.com

AcelRx | Innovative Therapies for Acute Pain

http://www.acelrx.com/pipeline/arx-03.html

AcelRx is currently focused on the development of ARX-04 and Zalviso, both of which are based on the Company's proprietary sublingual formulation technology. ARX-04 and Zalviso are completing Phase 3 clinical testing with new drug applications expected to be submitted in 2016. ARX-04 (sufentanil sublingual tablet, 30 mcg). ARX-04 is designed to provide a non-invasive treatment option for patients with moderate-to-severe acute pain, in multiple medically supervised settings ranging from the battlefield, c...

acelrx.com acelrx.com

AcelRx | Innovative Therapies for Acute Pain

http://www.acelrx.com/about/careers

At AcelRx Pharmaceuticals, we understand that our employees play a substantial role in our success. We are looking for employees with exceptional drive, commitment, and a collaborative spirit. We are looking to add highly skilled and dynamic individuals to our team who are passionate about improving the lives of patients with acute pain. We offer competitive compensation and benefits, and we recognize outstanding performance. View current open positions.

UPGRADE TO PREMIUM TO VIEW 23 MORE

TOTAL LINKS TO THIS WEBSITE

27

OTHER SITES

ir.acadia-pharm.com ir.acadia-pharm.com

Annual Report and Proxy - Investors - Acadia

Annual Report and Proxy. Annual Report and Proxy. Annual Report and Proxy. Annual Report and Proxy.

ir.acadiarealty.com ir.acadiarealty.com

Acadia Realty Trust - Investor Relations - Investor Relations

Acadia Realty Trust Conference Presentation at NAREIT’s REITWeek Investor Forum. 160;at 11:45 am ET. STRONG FUNDAMENTALS - FOCUSED ON OPPORTUNITY. A company with Strong Fundamentals, A company Focused on Opportunity. Acadia Realty Trust is a publicly traded real estate investment trust (REIT), which specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. American Stock Transfer and Trust Company. 160; 0.19. C Davi...

ir.acc.senshu-u.ac.jp ir.acc.senshu-u.ac.jp

専修大学学術機関リポジトリ(SI-Box)

紀要論文 / Departmental Bulletin Paper. 学位論文 / Thesis or Dissertation. 教材 / Learning Material. 会議発表論文 / Conference Paper. 学位論文 / Thesis or Dissertation 02. 学位論文 / Thesis or Dissertation (2013-). その他 / Others 02. 紀要論文 / Departmental Bulletin Paper 02. 学位論文 / Thesis or Dissertation 03. セルフアーカイブ / Self Archive. 広報資料 / Publicity Material. 図書 / Book 02. 報告書 科研費等 / Research Paper. 学術雑誌論文 / Journal Article. 紀要論文 / Departmental Bulletin Paper. 会議発表論文 / Conference Paper. 学位論文 / Thesis or Dissertation (-2012).

ir.accobrands.com ir.accobrands.com

ACCO Brands - Investor Relations - Investor Relations Home

Receive Materials by Email. Information About Mead Consumer and Office Products Merger. ACCO Brands Corporation (NYSE: ACCO) is one of the world's largest suppliers of select categories of branded school, office and consumer products and print finishing solutions, with revenues of $1.7 billion. We market products in over 100 countries across the globe through our own sales force and distribution networks. Our industry-leading brands and products include AT-A-GLANCE. 160; 0.32. Minimum 20 minute delay.

ir.accretivehealth.com ir.accretivehealth.com

Accretive Health, Inc. | Investor Relations | Investor Relations

Q2 2015 Accretive Health Inc Earnings Conference Call. 160;at 4:30 pm ET. Accretive Health is a leading provider of services and technology to healthcare providers. Our mission is to help our healthcare clients strengthen their financial stability and deliver better care at a more affordable cost to the communities they serve, increasing healthcare access for all. Our distinctive operating model that includes people, process, and sophisticated integrated technology helps our customers realize sus...CHICA...

ir.acelrx.com ir.acelrx.com

AcelRx Pharmaceuticals, Inc : Investors

Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. 160;at 4:30 pm ET. Q2 2015 AcelRx Pharmaceuticals, Inc. Earnings Conference Call. Monday, August 3, 2015 . 4:30 pm ET  . Click here for webcast. Click here to add this event to your calendar. ACRX Corporate Presentation - 5/7/15. 160; 0.13. Data as of 08/07/15 4:00 pm ET. Minimum 20 minute delay. AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results. Replication or redistribution of E...

ir.achillion.com ir.achillion.com

Investors | Achillion Pharmaceuticals

Presentations, Fact Sheet,. Life in New Haven. Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company’s mission to combat diseases by identifying and exploiting their unique vulnerabilities. Inspiring Science. Innovative Medicine. Mar 8, 2018. Achillion to Present at the Barclays Global Healthcare Conference. Feb 28, 2018. View all press releases ». Mar 15, 2018 at 11:15 AM ET. Barclays Global Healthcare Conference 2018.

ir.acorda.com ir.acorda.com

Acorda Therapeutics Inc - Investors

Investors span LayoutHomePageLayout Languageen-CA". Policy on Access to. Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Policy on Access to. March 26, 2018. Acorda Files Marketing Authorization Application for INBRIJA (levodopa inhalation powder). March 14, 2018. Acorda Rallies Parkinson’s Community in First-of-Its-Kind Initiative to Foster Better Conversations About Parkinson’s Symptoms.

ir.acsf.com ir.acsf.com

Investor Relations Home - Investor Relations - American Capital Senior Floating

Skip to main content. Dividend Reinvestment and Stock Purchase. Receive American Capital Senior Floating. 10-Q Q2 2015 (quarter ending June 30, 2015). 10-Q Q1 2015 (quarter ending March 31, 2015). American Capital Senior Floating, Ltd. Announces Monthly Cash Dividends of $0.097 per Share for August, September and October of 2015. American Capital Senior Floating Reports Net Investment Income of $0.32 per Share. American Capital Senior Floating, Ltd. Will Report Second Quarter 2015 Results on August 3.

ir.actiniumpharma.com ir.actiniumpharma.com

Investor Relations :: Actinium Pharmaceuticals, Inc. (ATNM)

Actinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 Conference. Jan 10, 2017. Ended Sep 30, 2016. Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. New York, NY 10016. 2469 E. Fort Union Blvd. Salt Lake City, UT 84121. Receive the latest news, events and updates! 2017 Actinium Pharmaceuticals, Inc.

ir.activepower.com ir.activepower.com

Investor Overview - Active Power Investors Relations

150 kVA â 1200 kVA). 750 kVA â 3 MVA). Our products are built on our elegant, field proven flywheel technology that delivers an unmatched combination of power density, reliability, and total cost of ownership. This combination enables our customers to achieve their availability, reliability, and budget goals. Q2 2015 Earnings Release. Q2 2015 Active Power, Inc. Earnings Conference Call. Q2 2015 â 10-Q. 160; 0.08. Data as of 08/07/15Â 4:00 pm ET. Minimum 20 minute delay. Active Power to Present at 43rd An...